Tremendous discussion of the SERENA-6 trial by Angie DeMichele, MD, MSCE, FASCO. Outstanding results, though not ready for clinical practice (yet). Important to take into account financial, psychological & systemic costs of the strategy. Make sure to review this presentation if you missed it.

Fabulous discussion from Dr. Alexandra Thomas on the evolving evidence for ctDNA across the continuum of breast cancer. Roadmap to understand when and how to use ctDNA in the clinic and what studies are still very much needed before changing practice Breast International Group

#ASCO25 DESTINY-Breast09 Sara Tolaney First-line T-DXd+P vs THP significantly prolongs PFS: 40.7 vs 26.9 mos Benefit seen across subgroups OS not mature PFS2 benefit (10% received T-DXd after THP) OncoAlert

Dear Colleagues at #ASCO25 An honor to Present our OncoAlert Faculty Sara Tolaney 🇺🇸 from Dana-Farber Who has just presented DESTINY-Breast09 T-DXd +pertuzumab vs taxane+trastuzumab+pertuzumab in FIRST Line Treatment of HER2+ advanced/metastatic #BreastCancer Matteo Lambertini, MD PhD

My poster neighbors— “The study was negative, but the friendship was positive” Heather McArthur, MD, MPH, FASCO Michail ignatiadis #ASCO25

I’ve been in the exercise oncology field for 20 years and for all of that time, the main criticism has been “show me a well controlled RCT.” Well, here it is. Exercise following adjuvant chemotherapy for colon cancer reduced recurrence and improves OVERALL SURVIVAL! #ASCO25

Such a powerful message 💪🏼💕⬇️ #ASCO24 OncoAlert

At #ASCO25 Clinical Science Symposium Angela Toss🇮🇹presented new insights from the 🌍BRCA BCY collab on the impact of BRCA variant #types in young pts with BC (n=3,294) Key findings: Truncating BRCA 1 PVs = worse OS Missense BRCA1/2 PVs = better OS Matteo Lambertini, MD PhD OncoAlert

Oral abstract early #BreastCancer session at #ASCO25: do we really need #carboplatin with neoadjuvant #taxane #trastuzumab #pertuzumab in #HER2+ disease? Very promising findings but survival outcomes are needed OncoAlert ASCO #bcsm

Another very important trial to help us de-escalating #chemotherapy burden in the neoadjuvant #HER2+ setting when #trastuzumab & #pertuzumab are offered…maybe too short giving just 4 cycles of #taxane ? OncoAlert ASCO

Shocking data 🤯 Effect size is huge, way larger than expected Urgent to seek reproduction/validation of the finding in further studies, given the potential implications on clinical practice and clinical trials (across oncology fields)

📌 Do We "Node" What to Do About the Axilla❓ Great discussion👏🏻 ✨Mediget Teshome, MD, FACS, MPH OncoAlert #OncoAlertAF #ASCO25

📌 Results from the ASTRRA trial ✨ Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor-positive breast cancer. ✨Jai Min Ryu, MD, PhD OncoAlert #OncoAlertAF #ASCO25

More data from the #BRCABCYcollaboration at #ASCO25 presented by Paola Zagami, MD showing the benefit of ovarian function suppression as adjuvant endocrine therapy in young #BRCA carriers with #BreastCancer OncoAlert Eva Blondeaux ASCO

One more NEJM paper for the #BreastCancer community at #ASCO25: very important data with use of #elinzanetant to help patients struggling with vasomotor symptoms during endocrine therapy OncoAlert

With synchronous publication in NEJM, Fatima Cardoso ABC Global Alliance shows Elinzanetant reduces vasomotor symptoms (hot flashes) for patients on ET with HR+ BC #ASCO25

Understanding information and trusting science 💕⬇️

1/6 Presented in Clinical Science Symposium at #ASCO25 new data from CARRIERS study Among >25,000 pts with BC, germline BRCA1 and BRCA2 carriers were linked to worse OS in ER+ BC No OS impact for ATM, CHEK2, or PALB2 (PALB2 a trend to worse OS) OncoAlert 🧵A thread here 👇

When I was first diagnosed with breast cancer 10 yrs ago, no-one told me about the importance of a healthy diet and regular exercise To be fair, as a breast surgeon I never told my patients either Times are changing Patients WANT to know what to eat Patients NEED to know about

We’re proud to share BIG’s 2024 Annual Report. This special 25th anniversary edition highlights a year of progress in breast cancer research. From key trials to global collaboration, see what we’ve achieved together. 📖 Read: bigagainstbreastcancer.org/wp-content/upl…